BACKGROUND In recent years,immune checkpoint inhibitors(ICIs)have demonstrated remarkable efficacy across diverse malignancies.Notably,in patients with advanced gastric cancer,the use of programmed death 1(PD-1)blocka...BACKGROUND In recent years,immune checkpoint inhibitors(ICIs)have demonstrated remarkable efficacy across diverse malignancies.Notably,in patients with advanced gastric cancer,the use of programmed death 1(PD-1)blockade has significantly prolonged overall survival,marking a pivotal advancement comparable to the impact of Herceptin over the past two decades.While the therapeutic benefits of ICIs are evident,the increasing use of immunotherapy has led to an increase in immune-related adverse events.CASE SUMMARY This article presents the case of a patient with advanced gastric cancer and chronic plaque psoriasis.Following sintilimab therapy,the patient developed severe rashes accompanied by cytokine release syndrome(CRS).Fortunately,effective management was achieved through the administration of glucocorticoid,tocilizumab,and acitretin,which resulted in favorable outcomes.CONCLUSION Glucocorticoid and tocilizumab therapy was effective in managing CRS after PD-1 blockade therapy for gastric cancer in a patient with chronic plaque psoriasis.展开更多
目的研究急性脑梗死(Acute cerebral infarction,ACI)风痰瘀阻证患者血清神经元特异性烯醇化酶(Neuron specific enolase,NSE)对辨证分型及病情的评估价值。方法选取2018年4月—2020年4月期间北京中医药大学附属护国寺中医医院收治的AC...目的研究急性脑梗死(Acute cerebral infarction,ACI)风痰瘀阻证患者血清神经元特异性烯醇化酶(Neuron specific enolase,NSE)对辨证分型及病情的评估价值。方法选取2018年4月—2020年4月期间北京中医药大学附属护国寺中医医院收治的ACI患者作为研究对象,根据中医辨证分型将风痰瘀阻证患者纳入观察组、其他分型纳入对照组,检测NSE、中性粒细胞/淋巴细胞比值(Neutrophil-to-lymphocyte ratio,NLR)、同型半胱氨酸(Homocysteine,Hcy)、缺血修饰白蛋白(Ischemia modified albumin,IMA)、C反应蛋白(C-reactive protein,CRP),采用美国国立卫生院卒中量表(The National Institutes of Health Stroke Scale,NIHSS)、改良Rankin量表(Modified Rankin Scale,mRS)及中医证候积分评价病情,随访90 d预后。结果观察组患者的血清NSE含量高于对照组(P<0.05)且NSE对风痰瘀阻证具有诊断价值,临界值为;观察组中NSE含量≥16.40 ng/ml患者的NIHSS、mRS评分、中医证候积分及NLR、Hcy、IMA、CRP水平均高于NSE含量<16.40 ng/ml患者(P<0.05);观察组中预后不良患者的血清NSE含量高于预后良好患者(P<0.05),且NSE对预后具有预测价值。结论血清NSE对ACI风痰瘀阻证具有诊断价值,也可用于病情及预后的评估。展开更多
基金Supported by Shaoxing Health Science and Technology Program,No.2022SY016,No.2022KY010.
文摘BACKGROUND In recent years,immune checkpoint inhibitors(ICIs)have demonstrated remarkable efficacy across diverse malignancies.Notably,in patients with advanced gastric cancer,the use of programmed death 1(PD-1)blockade has significantly prolonged overall survival,marking a pivotal advancement comparable to the impact of Herceptin over the past two decades.While the therapeutic benefits of ICIs are evident,the increasing use of immunotherapy has led to an increase in immune-related adverse events.CASE SUMMARY This article presents the case of a patient with advanced gastric cancer and chronic plaque psoriasis.Following sintilimab therapy,the patient developed severe rashes accompanied by cytokine release syndrome(CRS).Fortunately,effective management was achieved through the administration of glucocorticoid,tocilizumab,and acitretin,which resulted in favorable outcomes.CONCLUSION Glucocorticoid and tocilizumab therapy was effective in managing CRS after PD-1 blockade therapy for gastric cancer in a patient with chronic plaque psoriasis.
文摘目的研究急性脑梗死(Acute cerebral infarction,ACI)风痰瘀阻证患者血清神经元特异性烯醇化酶(Neuron specific enolase,NSE)对辨证分型及病情的评估价值。方法选取2018年4月—2020年4月期间北京中医药大学附属护国寺中医医院收治的ACI患者作为研究对象,根据中医辨证分型将风痰瘀阻证患者纳入观察组、其他分型纳入对照组,检测NSE、中性粒细胞/淋巴细胞比值(Neutrophil-to-lymphocyte ratio,NLR)、同型半胱氨酸(Homocysteine,Hcy)、缺血修饰白蛋白(Ischemia modified albumin,IMA)、C反应蛋白(C-reactive protein,CRP),采用美国国立卫生院卒中量表(The National Institutes of Health Stroke Scale,NIHSS)、改良Rankin量表(Modified Rankin Scale,mRS)及中医证候积分评价病情,随访90 d预后。结果观察组患者的血清NSE含量高于对照组(P<0.05)且NSE对风痰瘀阻证具有诊断价值,临界值为;观察组中NSE含量≥16.40 ng/ml患者的NIHSS、mRS评分、中医证候积分及NLR、Hcy、IMA、CRP水平均高于NSE含量<16.40 ng/ml患者(P<0.05);观察组中预后不良患者的血清NSE含量高于预后良好患者(P<0.05),且NSE对预后具有预测价值。结论血清NSE对ACI风痰瘀阻证具有诊断价值,也可用于病情及预后的评估。
